Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026

Castle Biosciences (CSTL) will release its third-quarter financial results after market close on Nov. 5, 2026, and host a webcast.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Castle Biosciences (CSTL) will release its third-quarter financial results after market close on Nov. 5, 2026, and host a webcast. The results will cover the quarter and nine months ended Sept. 30, 2026. Management will discuss the results at 4:30 p.m. Eastern time, followed by a brief question-and-answer session. A webcast replay will be available afterward.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/15/2026 - 07:00 AM EDT

FRIENDSWOOD, Texas, Oct. 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2026, after the close of market on Thursday, Nov. 5, 2026.

Company management will host a webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.

Webcast Details
The live webcast can be accessed here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=tHS7IFft, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/. Please access the webcast at least 10 minutes before the start time. A replay of the webcast will be available following its conclusion.

There will be a brief Question and Answer session following management commentary.

About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.

We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Instagram, Facebook and X. 

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com

Media Contact:
Allison Marshall
amarshall@castlebiosciences.com